-
Je něco špatně v tomto záznamu ?
Antifungal prophylaxis in adult patients with acute myeloid leukaemia treated with novel targeted therapies: a systematic review and expert consensus recommendation from the European Hematology Association
J. Stemler, N. de Jonge, N. Skoetz, J. Sinkó, RJ. Brüggemann, A. Busca, R. Ben-Ami, Z. Ráčil, V. Piechotta, R. Lewis, OA. Cornely
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, přehledy, systematický přehled
- MeSH
- akutní myeloidní leukemie * komplikace farmakoterapie MeSH
- antifungální látky terapeutické užití MeSH
- dospělí MeSH
- hematologie * MeSH
- kvalita života MeSH
- lidé MeSH
- mykózy * farmakoterapie MeSH
- triazoly terapeutické užití MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
- systematický přehled MeSH
On the basis of improved overall survival, treatment guidelines strongly recommend antifungal prophylaxis during remission induction chemotherapy for patients with acute myeloid leukaemia. Many novel targeted agents are metabolised by cytochrome P450, but potential drug-drug interactions (DDIs) and the resulting risk-benefit ratio have not been assessed in clinical trials, leading to uncertainty in clinical management. Consequently, the European Haematology Association commissioned experts in the field of infectious diseases, haematology, oncology, clinical pharmacology, and methodology to develop up-to-date recommendations on the role of antifungal prophylaxis and management of pharmacokinetic DDIs with triazole antifungals. A systematic literature review was performed according to Cochrane methods, and recommendations were developed by use of the Grading of Recommendations Assessment, Development and Evaluation Evidence to Decision framework. We searched MEDLINE, Embase, and Cochrane Library, including Central Register of Controlled Trials, for randomised controlled trials and systematic reviews published from inception to March 10, 2020. We excluded studies that were not published in English. Evidence for any identified novel agent that is active against acute myeloid leukaemia was reviewed for the following outcomes: incidence of invasive fungal disease, prolongation of hospitalisation, days spent in intensive-care unit, mortality due to invasive fungal disease, quality of life, and potential DDIs. Recommendations and consensus statements were compiled for each targeted drug for patients with acute myeloid leukaemia and each specific setting. Evidence-based recommendations were developed for hypomethylating agents, midostaurin, and the venetoclax-hypomethylating agent combination. For all other agents, consensus statements were given for specific therapeutic settings, specifically for the management of patients with relapsed or refractory acute myeloid leukaemia, monotherapy, and combination with chemotherapy. Antifungal prophylaxis is recommended with moderate strength in most settings, and strongly recommended if the novel acute myeloid leukaemia agent is administered in combination with intensive induction chemotherapy. For ivosidenib, lestaurtinib, quizartinib, and venetoclax, we moderately recommend adjusting the dose of the antileukaemic agent during administration of triazoles. This is the first guidance supporting clinical decision making on antifungal prophylaxis in recipients of novel targeted drugs for acute myeloid leukaemia. Future studies including therapeutic drug monitoring will need to determine the role of dosage adjustment of novel antileukaemic drugs during concomitant administration of CYP3A4-inhibiting antifungals with respect to adverse effects and remission status.
Department of Haematology Amsterdam University Medical Centers location AMC Amsterdam Netherlands
Department of Infectious Diseases Tel Aviv Sourasky Medical Center Tel Aviv Israel
Department of Pharmacy Radboud University Medical Center Nijmegen Netherlands
Department of Physiology Faculty of Medicine Masaryk University Brno Czech Republic
German Centre for Infection Research Partner Site Bonn Cologne Cologne Germany
Institute of Hematology and Blood Transfusion Prague Czech Republic
Nijmegen Institute for Health Sciences Radboud University Medical Center Nijmegen Netherlands
Radboudumc Center for Infectious Diseases Radboud University Medical Center Nijmegen Netherlands
Sackler Faculty of Medicine Tel Aviv University Tel Aviv Israel
Stem Cell Transplant Center Città della Salute e della Scienza Turin Turin Italy
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22018622
- 003
- CZ-PrNML
- 005
- 20220804134918.0
- 007
- ta
- 008
- 220720s2022 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/S2352-3026(22)00073-4 $2 doi
- 035 __
- $a (PubMed)35483397
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Stemler, Jannik $u Department I of Internal Medicine, Excellence Center for Medical Mycology, University of Cologne and University Hospital Cologne, Cologne, Germany; Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Ageing-Associated Diseases, University of Cologne and University Hospital Cologne, Cologne, Germany; German Centre for Infection Research, Partner Site Bonn-Cologne, Cologne, Germany
- 245 10
- $a Antifungal prophylaxis in adult patients with acute myeloid leukaemia treated with novel targeted therapies: a systematic review and expert consensus recommendation from the European Hematology Association / $c J. Stemler, N. de Jonge, N. Skoetz, J. Sinkó, RJ. Brüggemann, A. Busca, R. Ben-Ami, Z. Ráčil, V. Piechotta, R. Lewis, OA. Cornely
- 520 9_
- $a On the basis of improved overall survival, treatment guidelines strongly recommend antifungal prophylaxis during remission induction chemotherapy for patients with acute myeloid leukaemia. Many novel targeted agents are metabolised by cytochrome P450, but potential drug-drug interactions (DDIs) and the resulting risk-benefit ratio have not been assessed in clinical trials, leading to uncertainty in clinical management. Consequently, the European Haematology Association commissioned experts in the field of infectious diseases, haematology, oncology, clinical pharmacology, and methodology to develop up-to-date recommendations on the role of antifungal prophylaxis and management of pharmacokinetic DDIs with triazole antifungals. A systematic literature review was performed according to Cochrane methods, and recommendations were developed by use of the Grading of Recommendations Assessment, Development and Evaluation Evidence to Decision framework. We searched MEDLINE, Embase, and Cochrane Library, including Central Register of Controlled Trials, for randomised controlled trials and systematic reviews published from inception to March 10, 2020. We excluded studies that were not published in English. Evidence for any identified novel agent that is active against acute myeloid leukaemia was reviewed for the following outcomes: incidence of invasive fungal disease, prolongation of hospitalisation, days spent in intensive-care unit, mortality due to invasive fungal disease, quality of life, and potential DDIs. Recommendations and consensus statements were compiled for each targeted drug for patients with acute myeloid leukaemia and each specific setting. Evidence-based recommendations were developed for hypomethylating agents, midostaurin, and the venetoclax-hypomethylating agent combination. For all other agents, consensus statements were given for specific therapeutic settings, specifically for the management of patients with relapsed or refractory acute myeloid leukaemia, monotherapy, and combination with chemotherapy. Antifungal prophylaxis is recommended with moderate strength in most settings, and strongly recommended if the novel acute myeloid leukaemia agent is administered in combination with intensive induction chemotherapy. For ivosidenib, lestaurtinib, quizartinib, and venetoclax, we moderately recommend adjusting the dose of the antileukaemic agent during administration of triazoles. This is the first guidance supporting clinical decision making on antifungal prophylaxis in recipients of novel targeted drugs for acute myeloid leukaemia. Future studies including therapeutic drug monitoring will need to determine the role of dosage adjustment of novel antileukaemic drugs during concomitant administration of CYP3A4-inhibiting antifungals with respect to adverse effects and remission status.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a antifungální látky $x terapeutické užití $7 D000935
- 650 12
- $a hematologie $7 D006405
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a akutní myeloidní leukemie $x komplikace $x farmakoterapie $7 D015470
- 650 12
- $a mykózy $x farmakoterapie $7 D009181
- 650 _2
- $a kvalita života $7 D011788
- 650 _2
- $a triazoly $x terapeutické užití $7 D014230
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 655 _2
- $a systematický přehled $7 D000078182
- 700 1_
- $a de Jonge, Nick $u Department of Haematology, Amsterdam University Medical Centers, location AMC, Amsterdam, Netherlands
- 700 1_
- $a Skoetz, Nicole $u Evidence-based Oncology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne and University Hospital Cologne, Cologne, Germany
- 700 1_
- $a Sinkó, János $u Department of Haematology and HSCT, South-Pest Central Hospital, National Institute of Haematology and Infectious Diseases, Budapest, Hungary
- 700 1_
- $a Brüggemann, Roger J $u Department of Pharmacy, Radboud University Medical Center, Nijmegen, Netherlands; Nijmegen Institute for Health Sciences, Radboud University Medical Center, Nijmegen, Netherlands; Radboudumc Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, Netherlands
- 700 1_
- $a Busca, Alessandro $u Stem Cell Transplant Center, Città della Salute e della Scienza Turin, Turin, Italy
- 700 1_
- $a Ben-Ami, Ronen $u Department of Infectious Diseases, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
- 700 1_
- $a Ráčil, Zdeněk $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic; Department of Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Piechotta, Vanessa $u Evidence-based Oncology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne and University Hospital Cologne, Cologne, Germany
- 700 1_
- $a Lewis, Russell $u Department of Medical and Surgical Sciences, University of Bologna, Infectious Diseases-IRCCS S Orsola University Hospital, Bologna, Italy
- 700 1_
- $a Cornely, Oliver A $u Department I of Internal Medicine, Excellence Center for Medical Mycology, University of Cologne and University Hospital Cologne, Cologne, Germany; Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Ageing-Associated Diseases, University of Cologne and University Hospital Cologne, Cologne, Germany; Clinical Trials Centre Cologne, Faculty of Medicine, University of Cologne and University Hospital Cologne, Cologne, Germany; German Centre for Infection Research, Partner Site Bonn-Cologne, Cologne, Germany. Electronic address: yoliver.cornely@uk-koeln.de
- 773 0_
- $w MED00193479 $t The Lancet. Haematology $x 2352-3026 $g Roč. 9, č. 5 (2022), s. e361-e373
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35483397 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220720 $b ABA008
- 991 __
- $a 20220804134912 $b ABA008
- 999 __
- $a ok $b bmc $g 1822301 $s 1169865
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 9 $c 5 $d e361-e373 $e - $i 2352-3026 $m The Lancet. Haematology $n Lancet Haematol $x MED00193479
- LZP __
- $a Pubmed-20220720